Top Markets
Coin of the day
ERYTECH Pharma S.A. ERYTECH Pharma S.A.

ERYTECH Pharma S.A.

ERYP
Rang in Aktien #24695
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on... ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.
Aktienkurs
$0.95011029
Zuletzt synchronisiert: 2023-06-28
Marktkapitalisierung
$57.72M
Veränderung (1 Tag)
8.53%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel ERYTECH Pharma S.A. (ERYP)

Kategorie

Dividendenrendite-Verlauf für ERYTECH Pharma S.A. (ERYP)
Dividendenrendite (TTM) von ERYTECH Pharma S.A. (Aktienkürzel: ERYP) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für ERYTECH Pharma S.A. (ERYP) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH